Vuong Trieu - 17 Nov 2025 Form 4 Insider Report for Oncotelic Therapeutics, Inc. (OTLC)

Role
CHAIRMAN AND CEO, Director, 10%+ Owner
Signature
/s/ Vuong Trieu
Issuer symbol
OTLC
Transactions as of
17 Nov 2025
Transactions value $
$0
Form type
4
Filing time
19 Nov 2025, 15:45:27 UTC
Previous filing
10 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Trieu Vuong CHAIRMAN AND CEO, Director, 10%+ Owner 29397 AGOURA RD SUITE 107, AGOURA HILLS /s/ Vuong Trieu 19 Nov 2025 0001587074

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OTLC Series A Convertible Preferred Stock Award $0 +4.07K $0.00 4.07K 17 Nov 2025 Com-mon Stock 4.07M Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Series A Convertible Preferred Stock is convertible at any time at the option of the holder into Common Stock on a one-for-one thousand basis.
F2 The shares of Series A Convertible Preferred Stock were issued to Dr. Trieu as compensation pursuant to the accomplishment of performance milestones under a Restricted Stock Agreement dated November 17, 2025.